^
Association details:
| Biomarker: | BIRC3 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | BR (bendamustine + Rituxan (rituximab)) |
| Direction: | Resistant |
Evidence:
Source:
Title:
GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE
Published date:
05/17/2018
Excerpt:
To analyze progression-free survival (PFS) according to the presence of genetic defects in CLL patients treated with front line FCR or BR regimen...trend to shorter PFS in patients with BIRC3 mutations (19 vs. 28 m in BIRC3-wt patients; P = 0.056).
